AlphAIAlphAI — Financial news for AI agents
rttnews.comAUG 192 min read$IRIX

Iridex Posts Q2 Results, Glaucoma Segment Shows Strength

Iridex (IRIX) reported Q2 2026 revenue of $12.6M, down 7% YoY, with retina sales declining but glaucoma product sales up 19%. Net loss was $1.3M, or $0.07 per share. The company reaffirmed its annual revenue guidance of $51M-$53M. CEO Patrick Mercer cited strong glaucoma momentum and restructuring efforts for long-term profitability.

Original reporting
rttnews.com
Published Aug 19, 2026, 9:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 9:13 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$IRIX
Bearish
medium confidence
Mentioned
$IRIX
Relevance
6/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$IRIXBearishMed
01

Why it matters

Earnings miss may trigger short‑term sell pressure, but glaucoma product growth offers a positive narrative.

02

Market read

Micro‑cap medical device stock with recent earnings miss; relevance mainly to specialist investors.

03

What to watch

Potential upside from upcoming Pascal platform approvals and lower‑cost contract manufacturing.

Relevance 6/10Novelty 6/10Timing: overnight

Background

Iridex provides laser systems for eye disease treatment; Q2 results reflect mixed performance across product lines.

Company-level read

Ticker impact

$IRIXBearishMedium confidence
Context

Q2 2026 earnings released with revenue decline, loss widening and reaffirmed full-year guidance.

Expected impact

Potential downside of 5-10% over the next week.

Evidence & confidence

Revenue fell 7% YoY, net loss expanded, and guidance unchanged despite weak retina segment.

Market effects

Sector

Glaucoma device segment shows growth, while retina segment weakness may affect broader ophthalmic equipment sector.

Regional

Middle East disruptions and China sell‑through issues weigh on revenue.

Global

Limited to niche medical device investors.

Counterpoint

What could challenge this read

Reaffirmed guidance could be a floor if the company successfully executes cost cuts and regulatory approvals.

Key entities

  • Company
    Iridex Corporation

    Medical device maker for glaucoma and retinal treatments.

  • Executive
    Patrick Mercer

    President and CEO who commented on cash flow and restructuring.

Read at source← All news

Related articles

AUG 19
$IRIXMed

IRIDEX Corp (IRIX) (Q2 2026) Earnings Call Highlights: Cyclo-G6 Surges 35% as Company

IRIDEX Corp (IRIX) reported Q2 2026 earnings, highlighting a 35% surge in Cyclo-G6 probe sales. CEO Patrick Mercer expects low single-digit retina growth for the year, driven by regulatory approvals and promotions, despite headwinds in the Middle East and China. The company placed fewer Cyclo-G6 systems due to regulatory delays but anticipates higher numbers in Q4. Glaucoma growth was broad-based, with strong US and international performance. Revenue decline was attributed to retina business and

yahoo.com2 min
AUG 18
$IRIXMed

IRIDEX CORP (IRIX): Results of Operations and Financial Condition

IRIDEX CORP (IRIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Iridex Reports Second Quarter 2026 Financial Results MOUNTAIN VIEW, Calif., August 18, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for

SEC EDGAR 8-K6 min
SEP 20
$GEVMed

GE Vernova’s (GEV) $200 Billion Backlog is Coming Sooner than Expected

GE Vernova (GEV) CEO Scott Strazik expects the company's backlog to reach $200 billion in early 2027, earlier than anticipated. The company's Q2 2026 backlog was $176 billion, up 37% YoY, with revenue growing 22% YoY to $11.1 billion. GEV raised its 2026 revenue forecast to $45.5 billion-$46.5 billion. However, the company faces risks from AI bubble concerns and weakness in its Wind business.

insidermonkey.com3 min
SEP 20
$PLDMed

Prologis Sees Leasing Surge, Data Centers Fuel Growth Outlook

Prologis (PLD) reports a surge in leasing, with data centers driving growth. The company has secured 1.6 GW of power capacity and completed $2B in data center starts. U.S. logistics net absorption is 66M sq ft in Q2, with a 17% lease mark-to-market. Strong markets include Sun Belt, Texas, and Southern California. PLD expects e-commerce to reach 28-30% of U.S. retail sales by 2030.

finance.yahoo.com3 min
SEP 20
$RDDTMedAI 8/10

What Happens To Reddit Stock If Search Keeps Sending Fewer People?

Reddit (RDDT) stock is down 43% over the past year, trading near $153. Q2 2026 revenue grew 61% to $805 million, with an operating margin of 28.2%. Growth is driven by higher ad revenue per user, but search referrals are volatile. Management expects Q3 2026 revenue growth to slow to 47-49%. The company aims to improve user retention and become a destination site.

yahoo.com2 min
SEP 20
$ECOMed

Louis Navellier's stock scoring system spots 3 oil tanker stocks

Oil tanker companies Okeanis Eco Tankers (ECO), International Seaways (INSW), and DHT Holdings (DHT) report strong earnings due to higher shipping rates. ECO's Q2 revenue rose 239.6% YoY to $318.9M, INSW's revenue increased 138.8% YoY to $467.29M, and DHT's revenue grew 122.7% YoY to $284.8M. Analysts expect continued earnings growth for these companies.

yahoo.com3 min